ZILBRYSQ Trademark

Trademark Overview


On Friday, March 27, 2020, a trademark application was filed for ZILBRYSQ with the United States Patent and Trademark Office. The USPTO has given the ZILBRYSQ trademark a serial number of 88850346. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 23, 2023. This trademark is owned by Ra Pharmaceuticals, Inc.. The ZILBRYSQ trademark is filed in the Pharmaceutical Products and Medical Instrument Products categories with the following description:

Pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory disorder, a wound, a burn, an autoimmune disorder, a pulmonary disorder, a cardiovascular disorder, a neurological disorder, a kidney-related disorder, a diabetes-related disorder, an ocular disorder, and a pregnancy-related disorder; Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of fibrotic and inflammatory disorders; Pharmaceutical preparations for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations as anti-viral, anti-bacterial, or an...

Syringes for injections; Syringes for medical purposes; Syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication
zilbrysq

General Information


Serial Number88850346
Word MarkZILBRYSQ
Filing DateFriday, March 27, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 23, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 28, 2020

Trademark Statements


Goods and ServicesPharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory disorder, a wound, a burn, an autoimmune disorder, a pulmonary disorder, a cardiovascular disorder, a neurological disorder, a kidney-related disorder, a diabetes-related disorder, an ocular disorder, and a pregnancy-related disorder; Pharmaceutical preparations, for human use, for the prevention and treatment of disorders of metabolism, the nervous system, the immune system, the cardio-vascular system, the respiratory system, the musculo-skeletal system, and the genitourinary system; Pharmaceutical preparations for the treatment of fibrotic and inflammatory disorders; Pharmaceutical preparations for use in dermatology, nephrology, hepatology, rheumatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations as anti-viral, anti-bacterial, or anti-fungal agents
Translation of Words in MarkThe wording ZILBRYSQ has no meaning in a foreign language.
Goods and ServicesSyringes for injections; Syringes for medical purposes; Syringes for medical purposes sold empty which may be filled with pharmaceutical preparations, for human use, for the prevention and treatment of paroxysmal nocturnal hemoglobinuria, myasthenia gravis, an inflammatory indication, a wound, a burn, an autoimmune indication, a pulmonary indication, a cardiovascular indication, a neurological indication, a kidney-related indication, a diabetes-related indication, an ocular indication, and a pregnancy-related indication

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, April 1, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateWednesday, April 1, 2020
Primary Code010
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameRa Pharmaceuticals, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Party NameRa Pharmaceuticals, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02140

Trademark Events


Event DateEvent Description
Tuesday, March 31, 2020NEW APPLICATION ENTERED
Wednesday, April 1, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, June 18, 2020ASSIGNED TO EXAMINER
Thursday, June 18, 2020EXAMINERS AMENDMENT -WRITTEN
Thursday, June 18, 2020EXAMINERS AMENDMENT E-MAILED
Thursday, June 18, 2020NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, June 18, 2020EXAMINER'S AMENDMENT ENTERED
Thursday, June 18, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, June 22, 2020ASSIGNED TO LIE
Wednesday, July 8, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 28, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, July 28, 2020PUBLISHED FOR OPPOSITION
Tuesday, September 1, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, September 1, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 1, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, February 22, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, September 22, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, February 22, 2021SOU EXTENSION 1 FILED
Monday, February 22, 2021SOU EXTENSION 1 GRANTED
Wednesday, February 24, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 26, 2021SOU EXTENSION 2 FILED
Thursday, August 26, 2021SOU TEAS EXTENSION RECEIVED
Thursday, August 26, 2021SOU EXTENSION 2 GRANTED
Monday, October 25, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Saturday, August 28, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 25, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, October 25, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, October 25, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, December 13, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, December 13, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, December 13, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, December 13, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Monday, December 13, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, December 13, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, August 31, 2022SOU TEAS EXTENSION RECEIVED
Friday, March 4, 2022SOU TEAS EXTENSION RECEIVED
Friday, March 4, 2022SOU EXTENSION 3 FILED
Friday, March 4, 2022SOU EXTENSION 3 GRANTED
Tuesday, March 8, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 31, 2022SOU EXTENSION 4 FILED
Wednesday, August 31, 2022SOU EXTENSION 4 GRANTED
Friday, September 2, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 21, 2023SOU EXTENSION 5 GRANTED
Wednesday, March 8, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, March 8, 2023SOU EXTENSION 5 FILED
Tuesday, March 21, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, March 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, October 23, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 23, 2023ABANDONMENT - NO USE STATEMENT FILED